For all the buzz surrounding Personalized Health Management (PHM), many are still unsure of exactly what the term (and practice) really means. What will this new era of health management bring? Is PHM the same as eHealth, or Medicine 2.0?
To answer these questions and to explore PHM's pros and cons, its potential for innovation, and its promise for the future, join swissnex San Francisco along with the Consulates general of Canada and France, Advance, and the Denmark Innovation Center for a panel discussion on PHM with representatives from the health industry, government, biotech and venture fields, and the media.
Moderator Anne Hanham, of Burrill & Company, leads the discussion with panelists Thomas Goetz, author and editor at WIRED Magazine; President and CEO Martin LeBlanc, of Caprion Proteomics; Joakim Mikkelsen, healthcare and life sciences attaché for the Embassy of Denmark in Washington D.C.; and Molly Porter, director of training for Kaiser Permanente International.
Thomas Goetz is a writer, entrepreneur and health care innovator. He is the author of the new book, The Remedy, which was chosen as a Best Book of the month by both iTunes and Amazon. His previous book, The Decision Tree: Taking Control of Your Health in the New Era of Personalized Medicine, was chosen by the Wall Street Journal as a Best Health book of 2010.
Thomas is also co-founder of Iodine, a health technology company with the mission of turning medical research data into clear and actionable tools for ordinary people to make better decisions about their health.
Anne Hanham is the managing director at Burrill & Company, and is currently on the Board of Directors of Adlyfe, Elbion, Endocyte, Logical Therapeutics, Neosil, and Veritas Medicine.
She was a co-founder and vice president of clinical and regulatory affairs at InterMune Pharmaceuticals, and prior to that, she served as the senior director for oncology product development at Otsuka Pharmaceuticals as well as medical director for Celtrix Pharmaceuticals. She also worked for Becton Dickinson in both regulatory and clinical affairs for the monoclonal antibody program, and as a regulatory toxicologist with the health protection branch of Health and Welfare Canada.
Hanham holds a Ph.D. from the University of British Columbia, a master's degree from Simon Fraser University, and a bachelor's degree from the University of Toronto. She was Board Certified in toxicology in 1986.
President and CEO Martin LeBlanc, of Caprion Proteomics, led the development and implementation of Caprion's proteomics technology when he co-founded the company. He also helped establish profitable proteomics services by creating multiple revenue-generating biomarker and target identification alliances with over 20 major pharmaceutical companies. In 2007, he led the spin-out, recapitalization, and sale of Caprion Proteomics to Great Point Partners, LLC, and in 2008 concluded Caprion's equity financing and strategic distribution alliance with Covance Inc., a leading global provider of drug development services. Prior to Caprion, LeBlanc worked as a management consultant with McKinsey & Company, as vice-president of sales and marketing (and later as general manager) at Advanced Bioconcept Ltd.
He is a member of the Board of Directors of Victhom Human Bionics (TSX: VHB), Mispro Pharma, Soricimed Pharmaceuticals, and Chairman of the Board of the Atlantic Cancer Research Institute, and he earned his bachelor's degree in economics from the University of Moncton prior to completing a master's in economics and politics at Oxford University as a Rhodes Scholar.
Joakim Mikkelsen is the healthcare and life sciences attaché for the Embassy of Denmark in Washington D.C. Managing trade and export promotion of healthcare-based products and services, he works closely with key stakeholders as well as the US Department for Health and Human Services, the FDA, CMS, NIH, as well as patient groups and special therapeutic associations advancing Danish investments in life sciences, prevention, and preparedness programs. He chairs a number of educational seminars for industry with the overall goal of mitigating risk in drug development and the drug approval process, decreasing time to market, and widespread adoption.
Prior to Danish Embassy, he was part of the management team at CMC Biopharmaceuticals, a CMO for protein-based biopharmaceuticals. He holds an international degree in Management of Technology from Copenhagen Business School and Rouen Graduate School of Management in France.
He also has certificates from the University of Copenhagen, the FDA CDRH, and FDA CDER, and has taken part in executive pharmaceutical and biotech programs at the Wharton School and Rutgers Business School.
Molly Porter is the director of training for Kaiser Permanente International, where she develops programs about Kaiser Permanente for international healthcare leaders in the US and other countries. She has represented Kaiser Permanente in Brazil, Canada, Denmark, Germany, the Netherlands, the United Kingdom, and Spain.
Porter has worked for Kaiser Permanente for 19 years, holding positions at the national, regional, and local levels. Previously, she spent three years as the communications manager in East Bay Public Affairs, serving both the Oakland and Richmond medical centers. Earlier in her career, she worked as a communications consultant for Kaiser Permanente Information Technology and as a manager in Northern California and Program Offices Corporate Communications. She has also run her own communications training and consulting business, where her clients included the US Agency for International Development, PricewaterhouseCoopers, McKesson Health Systems, Blue Shield of California, and Kaiser Permanente.
She earned her bachelor's degree in romance languages and literature from Antioch University and studied in Paris, France, and Cuernavaca, Mexico.
Extent of continuing physical, emotional, mental, and social ability to cope with one's environment. Good health is harder to define than bad health (which can be equated with presence of disease) because it must convey a more positive concept than mere absence of disease, and there is a variable area between health and disease. A person may be in good physical condition but have a cold or be mentally ill. Someone may appear healthy but have a serious condition (e.g., cancer) that is detectable only by physical examination or diagnostic tests or not even by these.
YES YES YES
Establish a base for protein markers, metabolic markers, and DNA, and epigenetics for each individual. Over time we will all benefit from looking at the patterns of change in our levels and looking for group shifts that indicate health problems. Eric